Journal of Urgent Care Medicine

Newly Approved DHE Nasal Powder Treats Migraine

The Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder 5.2 mg for the acute treatment of migraine in adults with or without aura. The new product is currently the only DHE nasal powder available for this indication, according to a press release from manufacturer Satsuma. Clinical studies demonstrated that the formulation offers rapid absorption, quick attainment of high plasma DHE concentrations, and sustained levels over time. It was generally well tolerated both …

Phase 3 Migraine Clinical Trial Finds a Prime Site in Urgent Care

Hometown Urgent Care in Ohio is one of just 18 sites participating in a new phase 3 clinical trial to assess a prospective treatment for adult patients with acute migraines. The trial will compare pain freedom in subjects who’ve taken the drug rimegepant vs placebo in the acute treatment of migraine at 2 hours postdose. It will also take into account freedom from the “most bothersome symptom” (nausea, phonophobia, or photophobia) in the rimegepant group …